- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07836478
Neurocognitive Integrity After Proton Therapy for Brain Tumor (PROTON MIND)
Prospective Evaluation of Neurocognitive Integrity After Proton Therapy for Brain Tumor
Radiation therapy remains a cornerstone in the management of both benign and malignant intracranial tumors, either as monotherapy or combined with surgery and/or chemotherapy. Despite its therapeutic benefits, it is frequently associated with potential long-term adverse effects, with neurotoxicity posing a major challenge, especially in young patients affected by benign primary tumors.
Przegląd badań
Status
Szczegółowy opis
In the brain, late radiotoxicities typically manifest as cognitive dysfunction, leukoencephalopathy, brain atrophy, brain tissue necrosis, cerebrovascular complications, endocrinopathies, and/or secondary malignant neoplasms.
Radiation-induced hippocampal injury, in particular, significantly contributes to cognitive impairment, while broader central nervous system effects arise through multiple mechanisms, including vascular injury, neuronal depletion, chronic inflammation, demyelination, and tissue necrosis.
The severity of cognitive dysfunction depends on multiple factors, including the location and the volume of the tumor, the total radiation dose administered, the fractionation regimen, and the individual susceptibility of the patient, as well as comorbidities (e.g., diabetes, etc.) and concomitant drugs.
The distinct physical characteristics of proton therapy, such as a reduced entrance dose, an eliminated exit dose, and a Bragg peak, provide clear dosimetric advantages over conventional photon treatments. Pencil-beam scanning further improves on earlier passive scattering approaches by delivering modulated proton beamlets for superior target conformality and reduced neutron scatter, thereby limiting low- and intermediate- dose exposure to cranial organs at risk (OARs) while preserving adequate dose coverage within the target volume.
From a radiobiological standpoint, these properties suggest that proton therapy may present a more favorable risk-benefit balance compared to photon-based modalities, particularly for long-term clinical outcomes. It achieves a drastic reduction in the integral dose, offering substantial benefit in decreasing radiation-induced second malignancies, making it mandatory for children when available.
Proton therapy is well established for treating pediatric tumors, CNS tumors such as low-grade gliomas (LGG) and meningiomas, especially if near the optic pathway or brainstem, and all the benign tumors in young patients. In these cases, the primary goal extends beyond curing the disease to preserving neurological and cognitive functions.
Typ studiów
Zapisy (Szacowany)
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Gabriella Pravettoni
- Numer telefonu: +39 0257489207
- E-mail: Gabriella.Pravettoni@ieo.it
Lokalizacje studiów
-
-
Italy
-
Milan, Italy, Włochy, 20141
- European Institute of Oncology, Milan
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Patients affected by primary central nervous system tumors and eligible for protontherapy as adjuvant or radical treatment
Opis
Inclusion Criteria:
- Primary tumors of Brain Tumor (CNS), benign and malignant
- Age ≥ 18 years
- Patients able to speak and read the local language(s) fluently
- Acceptance and signature of informed consent
- Radiological diagnosis, biopsy, or previous surgery
- Concomitant medical therapy is allowed
Exclusion Criteria:
- Previous brain radiotherapy (any form)
- High-grade gliomas
- Patients with concomitant neurological or psychiatric disorders.
- Pregnancy
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
The presence of cognitive impairment
Ramy czasowe: From the end of Protontherapy through study completion, an average of 1 year.
|
The primary endpoint will be the presence of cognitive impairment during the first 5 years after enrollment, as measured by a comprehensive neuropsychological assessment. |
From the end of Protontherapy through study completion, an average of 1 year.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Perceived cognitive impairment
Ramy czasowe: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Functional Assessment of Cancer Therapy-cognition (FACT-cog) 37 items will be completed (score 1-4) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Depressive symptoms
Ramy czasowe: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
At Beck Depression Inventory-II (BDI-II) 21 items will be completed (score 0-3) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Anxiety
Ramy czasowe: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For State-Trait Anxiety Inventory (STAI) 40 items will be completed (score 1-4) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Quality of Life data (QoL) - EORTC QLQ C30 questionnaires.
Ramy czasowe: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For EORTC QLQ C30, 30 items will be completed (score 1-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Sleep quality
Ramy czasowe: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Pittsburgh Sleep Quality Index (PSQI) 24 items will be completed (score 0-3) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Cognitive Reserve
Ramy czasowe: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Cognitive Reserve Index questionnaire (CRIq) 20 items will be completed (core 0-1) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Global functioning
Ramy czasowe: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Montreal Cognitive Assessment (MoCA) 30 items will be completed (score 1-5). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Learning and Verbal Memory
Ramy czasowe: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey Auditory Verbal Learning Test (RAVLT) 15 items will be completed (score 0-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Working memory
Ramy czasowe: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Corsi Span backward/forward 18 items will be completed (score 0-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Visual memory
Ramy czasowe: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey-Osterrieth complex figure -recall 18 items will be completed (score 0-2). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Visuospatial abilities
Ramy czasowe: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey-Osterrieth complex figure -copy 18 items will be completed (score 0-2). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Executive function
Ramy czasowe: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Frontal Assessment Battery (FAB) 30 items will be completed (score 0-3). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Attention
Ramy czasowe: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Symbol digit modalities test (SDMT) 110 items will be completed (score 0-1) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
- UID 5445
- L2-684 (Inny identyfikator: Comitato Etico Lombardia 2)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .